金达威：10月24日召开董事会会议

Group 1 - The core point of the article is that Jindawei (SZ 002626) held its ninth board meeting on October 24, 2025, to discuss the revision of the "Board Compensation and Assessment Committee Rules" [1] - For the first half of 2025, Jindawei's revenue composition was as follows: industrial accounted for 98.5%, pharmaceutical raw materials 1.43%, and other businesses 0.07% [1] - As of the report date, Jindawei's market capitalization was 12.5 billion yuan [1] Group 2 - The article highlights that Chinese innovative drugs have generated $80 billion in overseas licensing this year, indicating a hot secondary market in biomedicine, while the primary market is facing fundraising challenges [1]